SonoScape Medical Corp
SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally. The company offers ultrasound medical imaging products comprising trolley and portable color dopplers, B/W ultrasounds, and transducers; endoscopic diagnosis and treatment products consisting of image process… Read more
SonoScape Medical Corp (300633) - Net Assets
Latest net assets as of September 2025: CN¥3.12 Billion CNY
Based on the latest financial reports, SonoScape Medical Corp (300633) has net assets worth CN¥3.12 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.12 Billion) and total liabilities (CN¥996.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.12 Billion |
| % of Total Assets | 75.78% |
| Annual Growth Rate | 19.91% |
| 5-Year Change | 131.1% |
| 10-Year Change | 448.96% |
| Growth Volatility | 21.15 |
SonoScape Medical Corp - Net Assets Trend (2012–2024)
This chart illustrates how SonoScape Medical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SonoScape Medical Corp (2012–2024)
The table below shows the annual net assets of SonoScape Medical Corp from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.11 Billion | -1.20% |
| 2023-12-31 | CN¥3.15 Billion | +14.82% |
| 2022-12-31 | CN¥2.74 Billion | +16.33% |
| 2021-12-31 | CN¥2.36 Billion | +75.11% |
| 2020-12-31 | CN¥1.34 Billion | -4.22% |
| 2019-12-31 | CN¥1.40 Billion | +7.11% |
| 2018-12-31 | CN¥1.31 Billion | +23.75% |
| 2017-12-31 | CN¥1.06 Billion | +47.11% |
| 2016-12-31 | CN¥720.11 Million | +27.18% |
| 2015-12-31 | CN¥566.21 Million | +27.29% |
| 2014-12-31 | CN¥444.81 Million | +21.84% |
| 2013-12-31 | CN¥365.08 Million | +3.77% |
| 2012-12-31 | CN¥351.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SonoScape Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 485.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.41 Billion | 45.46% |
| Common Stock | CN¥432.71 Million | 13.92% |
| Other Components | CN¥1.26 Billion | 40.62% |
| Total Equity | CN¥3.11 Billion | 100.00% |
SonoScape Medical Corp Competitors by Market Cap
The table below lists competitors of SonoScape Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hsino Tower Group Co., Ltd.
SHG:601096
|
$697.19 Million |
|
Hangzhou XZB Tech Co Ltd
SHG:603040
|
$697.24 Million |
|
CP Axtra Public Company Limited
BK:CPAXT
|
$697.92 Million |
|
Tongyang Inc
KO:001527
|
$697.96 Million |
|
Man Wah Holdings Limited
F:AAM
|
$697.13 Million |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
$696.96 Million |
|
AEHR TEST SYSTEMS DL-01
F:AYB
|
$696.69 Million |
|
Regis Healthcare Ltd
AU:REG
|
$696.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SonoScape Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,145,953,651 to 3,108,222,479, a change of -37,731,172 (-1.2%).
- Net income of 142,397,372 contributed positively to equity growth.
- Dividend payments of 144,335,404 reduced retained earnings.
- Share repurchases of 60,039,195 reduced equity.
- Other comprehensive income decreased equity by 335,493,311.
- Other factors increased equity by 359,739,366.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥142.40 Million | +4.58% |
| Dividends Paid | CN¥144.34 Million | -4.64% |
| Share Repurchases | CN¥60.04 Million | -1.93% |
| Other Comprehensive Income | CN¥-335.49 Million | -10.79% |
| Other Changes | CN¥359.74 Million | +11.57% |
| Total Change | CN¥- | -1.20% |
Book Value vs Market Value Analysis
This analysis compares SonoScape Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 27.94x to 3.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.94 | CN¥26.20 | x |
| 2013-12-31 | CN¥1.03 | CN¥26.20 | x |
| 2014-12-31 | CN¥1.25 | CN¥26.20 | x |
| 2015-12-31 | CN¥1.55 | CN¥26.20 | x |
| 2016-12-31 | CN¥1.99 | CN¥26.20 | x |
| 2017-12-31 | CN¥2.73 | CN¥26.20 | x |
| 2018-12-31 | CN¥3.27 | CN¥26.20 | x |
| 2019-12-31 | CN¥3.51 | CN¥26.20 | x |
| 2020-12-31 | CN¥3.36 | CN¥26.20 | x |
| 2021-12-31 | CN¥5.89 | CN¥26.20 | x |
| 2022-12-31 | CN¥6.40 | CN¥26.20 | x |
| 2023-12-31 | CN¥7.27 | CN¥26.20 | x |
| 2024-12-31 | CN¥7.23 | CN¥26.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SonoScape Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.07%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.39x
- Recent ROE (4.58%) is below the historical average (16.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 38.91% | 26.83% | 0.78x | 1.86x | CN¥96.55 Million |
| 2013 | 19.35% | 11.93% | 0.95x | 1.71x | CN¥34.14 Million |
| 2014 | 29.62% | 20.60% | 0.75x | 1.93x | CN¥87.27 Million |
| 2015 | 18.70% | 15.44% | 0.73x | 1.65x | CN¥49.25 Million |
| 2016 | 18.11% | 18.13% | 0.71x | 1.41x | CN¥58.42 Million |
| 2017 | 17.94% | 19.21% | 0.74x | 1.26x | CN¥84.08 Million |
| 2018 | 19.27% | 20.59% | 0.67x | 1.40x | CN¥121.52 Million |
| 2019 | 7.23% | 8.10% | 0.52x | 1.72x | CN¥-38.89 Million |
| 2020 | -3.44% | -3.98% | 0.52x | 1.67x | CN¥-180.76 Million |
| 2021 | 10.50% | 17.12% | 0.48x | 1.28x | CN¥11.73 Million |
| 2022 | 13.50% | 20.98% | 0.50x | 1.29x | CN¥95.83 Million |
| 2023 | 14.45% | 21.43% | 0.56x | 1.20x | CN¥139.84 Million |
| 2024 | 4.58% | 7.07% | 0.47x | 1.39x | CN¥-168.42 Million |
Industry Comparison
This section compares SonoScape Medical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,294,791,972
- Average return on equity (ROE) among peers: 19.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SonoScape Medical Corp (300633) | CN¥3.12 Billion | 38.91% | 0.32x | $697.16 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $398.02 Million | 18.74% | 0.22x | $325.38 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $7.49 Billion | 23.47% | 0.34x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $1.75 Billion | 26.55% | 0.28x | $399.08 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $2.85 Billion | 49.59% | 0.20x | $288.07 Million |
| Lepu Medical Tech Beijing (300003) | $16.74 Billion | 1.48% | 0.47x | $2.77 Billion |
| INKON Life Technology Co Ltd (300143) | $116.90 Million | 17.41% | 0.92x | $621.57 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $527.51 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $377.92 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $105.32 Million | 39.32% | 0.45x | $271.42 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $954.87 Million |